Connect with us

Biotech

Innitius closes a €600,000 round led by Banco Santander

The Basque Country-based startup gets funding from the Botín Foundation, Seed Capital Bizkaia and Wa4steam to improve Fine Birth, a device to detect false signs of premature birth, and hopes to get $565,000 (€500,000) more in July. The Botin Foundation’s Mind the Gap program encourages biotech entrepreneurship to enable technologies with commercial potential to reach the market.

Published

on

This picture show a pregnant woman.

The Vizcaya-based startup Innitius closed a $678,000 (€600,000) investment round from Banco Santander, through the Mind the Gap program of the Botín Foundation, Seed Capital Bizkaia and Wa4steam. The company’s objective is to extend the investment round to $1.24 million (€1.1 million) in July. 

Fine Birth is the device developed by Innitius and allows the detection of false signs of premature birth. The company will use the funding from the round to improve the quality system and to carry out a kind of clinical trial to perfect the algorithm on which the device is based. The Botin Foundation’s Mind the Gap program encourages biotech entrepreneurship to enable technologies with commercial potential to reach the market. The same foundation invested half a million euros in Innitius a year ago. 

If you want to read more about Innitius new device to detect false signs of premature birth and to find out the latest finance news in the world, download the Born2Invest mobile app.

Innitius is also supported by a group of investors

On the other hand, Seed Capital Bizkaia is a program that aims to develop innovative business projects and Wa4steam is a group formed by investors that offers economic support to startups. In addition, a business angel has also participated in the operation, but whose name has not been divulged. 

The Fine Birth device allows the detection of false signs of premature birth through an intravaginal probe that transmits torsional waves, which directly measure the consistency of the cervical tissue. The co-founder and CEO of Innitius, Rubén Molina, has commented that “85% of pregnant women admitted are diagnosed with false threats of premature birth” and each admission costs the health system $23,700 (€21,000). 

Molina has reflected that they are holding conversations with various health centers to carry out the clinical trials 

Some of these are the Biocruces Bizkaia Health Research Institute, other hospitals in the Basque Country, the University Hospital of Torrejón, the Virgen de la Arrixaca University Clinical Hospital in Murcia and the San Cecilio University Hospital in Granada.  “Each admission for false indications of premature birth means  $23,700 (€21,000) to the health system,” said Rubén Molina Innitius, a spin-off from the University of Granada, but the founders decided to move to the Basque Country at the end of 2019 because of a strategic decision. Molina stated that Vizcaya is the “best region to develop Fine Birth because of the exploration companies are doing and because we are entering an investment center.” 

SEE ALSO  One Belt, One Road strategy: How China plans to conquer the world economy

“The coronavirus affected us, we wanted to close the round at the end of March,” said the CEO of the startup. Molina regrets that, before the health crisis, the company got the first $339,000 (€300,000), but the “pandemic has paralyzed the investment rounds.”

Looking ahead, Molina said that “there is no point in focusing locally, so we already have in mind to open the next round within a year of $4.5 or $5.6 million (€4 or €5 million).” This funding would allow the company to conduct the regulatory clinical trial to obtain approval from the US Food and Drug Administration (FDA) and the European Union’s CE marking. 

“The United States is the first market for our product due to its decentralized health system,” explained Innitius’ CEO. Rubén Molina has a degree in Construction Engineering and a Masters in Civil Engineering from the University of Granada. In addition, the CEO of Innitius was a research associate at the university for two years and has participated in various entrepreneurship programs such as CaixaImpulse 2016, from Caixa Capital Risc, and Xplorer, from Banco Santander.  

Innitius has six employees, most of them related to the University of Granada

Currently, six people work at Innitius, five in Spain and one in the United States, who is Todd Snowden and is in charge of the development business. Carlos Álvarez-Iglesias is the operations director of the company and is involved in several innovative projects. Finally, Alberto García is the research and development manager of Innitius. 

Ten people were the founding partners of the startup, besides some engineers, also health professionals such as Francisca Molina, a specialist in maternal-fetal medicine and fetal therapy. Also, co-founders of Innitius are civil engineer Guillermo Rus, computer and telecommunications engineer Miguel Ángel Carvajal, and industrial engineer Rafael Muñoz.

SEE ALSO  The majority of Bitcoin and crypto owners are open to taxation

__

(Featured image by StockSnap via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.